Abstract LB266: A multicenter phase 1-2a clinical study of Orotecan® (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors

Authors: Jeffrey Bacha, Dennis Brown, James Geller, Javier Oesterheld, Patrick Thompson, Aerang Kim, Meghann McManus, Sarath Kanekal, Markos Leggas, Lorena Lopez, Neil Sankar, Noymi Yam, Lars Wagner

Published: 2025-04-25

DOI: 10.1158/1538-7445.am2025-lb266

Source: Full article